Premium
Soluble Fcɛ RI : A biomarker for IgE‐mediated diseases
Author(s) -
MoñinoRomero Sherezade,
Lexmond Willem S.,
Singer Josef,
Bannert Christina,
Amoah Abena S.,
Yazdanbakhsh Maria,
Boakye Daniel A.,
JensenJarolim Erika,
Fiebiger Edda,
Szépfalusi Zsolt
Publication year - 2019
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.13734
Subject(s) - biomarker , immunoglobulin e , immunology , allergy , medicine , chemistry , antibody , biochemistry
To the Editor, Soluble IgE receptors interact with IgE in the extracellular matrix and are important in the regulation of immune diseases. Soluble FcεRII (sCD23) and galectin‐3 (εBP) are currently used as biomarkers, though correlation data on serum titers and severity of allergies are controversial. FcεRI, the high‐affinity IgE Fc receptor, is expressed on several innate cell types, and a truncated version of the IgE‐binding alpha subunit is found as a soluble isoform (sFcεRI) in human serum. In circulation, sFcεRI is mostly detected as a complex with IgE. This observation raises the question of how sFcεRI affects detection of serum IgE titers. In order to assign clinical implications of sFcεRI, we assessed serum titers in its total and IgE‐bound forms in different IgE‐ mediated diseases in 312 individuals. We compared pediatric populations with primary food allergies (n = 59), insect venom allergies (n = 9), allergic asthma (n = 24), atopic dermatitis (n = 25), food‐sensitized nonallergic children (n = 31), and nonallergic controls (n = 17). Additionally, other sensitized groups and controls (n = 147) were included in the study (Table S1-S4).